Top 50 of 274 AI-discovered patents by relevance.
Composition (18) 95/100 7910098 Grant: 2011-03-22 | Exp: 2031-03-17 Anti-VEGF antibodies▼ 95/100 11820816 Grant: 2023-11-21 | Exp: 2043-11-16 Anti-VEGF antibodies and methods of use▼ 95/100 9079953 Grant: 2015-07-14 | Exp: 2035-07-09 Anti-VEGF antibodies and their uses▼ 90/100 9815893 Grant: 2017-11-14 | Exp: 2037-11-09 Anti-VEGF antibodies and their uses▼ 90/100 10683345 Grant: 2020-06-16 | Exp: 2040-06-11 Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases▼ 90/100 8921537 Grant: 2014-12-30 | Exp: 2034-12-25 Anti-VEGF antibodies▼ 88/100 11111304 Grant: 2021-09-07 | Exp: 2041-09-02 Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2)▼ 88/100 9815788 Grant: 2017-11-14 | Exp: 2037-11-09 Anti-angiogenic compounds▼ 85/100 12084503 Grant: 2024-09-10 | Exp: 2044-09-05 Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment▼ 85/100 11254738 Grant: 2022-02-22 | Exp: 2042-02-17 Synthetic antibodies against VEGF and their uses▼ 85/100 9777059 Grant: 2017-10-03 | Exp: 2037-09-28 Anti-VEGF antibodies▼ 85/100 7090834 Grant: 2006-08-15 | Exp: 2026-08-10 Vascular endothelial cell growth factor variants and uses thereof▼ 85/100 9273113 Grant: 2016-03-01 | Exp: 2036-02-25 Methods of inhibiting vascular endothelial growth factor activity▼ 82/100 7427596 Grant: 2008-09-23 | Exp: 2028-09-18 Variants of vascular endothelial cell growth factor, their uses, and processes for their production▼ 82/100 8604185 Grant: 2013-12-10 | Exp: 2033-12-05 Inhibitors of angiopoietin-like 4 protein, combinations, and their use▼ 82/100 8268314 Grant: 2012-09-18 | Exp: 2032-09-13 Bispecific anti-VEGF/anti-ANG-2 antibodies▼ 82/100 7378507 Grant: 2008-05-27 | Exp: 2028-05-22 PRO217 polypeptides▼ 80/100 8945552 Grant: 2015-02-03 | Exp: 2035-01-29 Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies▼
Formulation (8) 95/100 12427193 Grant: 2025-09-30 | Exp: 2045-09-25 Subcutaneous anti-HER2 antibody formulations and uses thereof▼ 92/100 10377831 Grant: 2019-08-13 | Exp: 2039-08-08 Highly concentrated pharmaceutical formulations▼ 92/100 11370833 Grant: 2022-06-28 | Exp: 2042-06-23 Antibody formulations▼ 90/100 10010611 Grant: 2018-07-03 | Exp: 2038-06-28 Antibody formulations▼ 90/100 10280227 Grant: 2019-05-07 | Exp: 2039-05-02 Highly concentrated pharmaceutical formulations▼ 88/100 9226961 Grant: 2016-01-05 | Exp: 2035-12-31 Antibody formulation▼ 85/100 8008447 Grant: 2011-08-30 | Exp: 2031-08-25 Crystallization of antibody or fragment thereof▼ 82/100 9345661 Grant: 2016-05-24 | Exp: 2036-05-19 Subcutaneous anti-HER2 antibody formulations and uses thereof▼
Method of Use (16) 92/100 9090700 Grant: 2015-07-28 | Exp: 2035-07-23 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2▼ 90/100 11384142 Grant: 2022-07-12 | Exp: 2042-07-07 Combination therapy for the treatment of ovarian cancer▼ 88/100 9918950 Grant: 2018-03-20 | Exp: 2038-03-15 Targeted treatment of anerobic cancer▼ 88/100 7449184 Grant: 2008-11-11 | Exp: 2028-11-06 Fixed dosing of HER antibodies▼ 88/100 10617755 Grant: 2020-04-14 | Exp: 2040-04-09 Combination therapy for the treatment of glioblastoma▼ 85/100 9795672 Grant: 2017-10-24 | Exp: 2037-10-19 Treatment with anti-VEGF antibodies▼ 85/100 7622115 Grant: 2009-11-24 | Exp: 2029-11-19 Treatment with anti-VEGF antibodies▼ 85/100 12409178 Grant: 2025-09-09 | Exp: 2045-09-04 Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors▼ 85/100 9895441 Grant: 2018-02-20 | Exp: 2038-02-15 Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists▼ 85/100 10208355 Grant: 2019-02-19 | Exp: 2039-02-14 Method of treatment for glioblastoma by administering a VEGF antagonist▼ 85/100 11034757 Grant: 2021-06-15 | Exp: 2041-06-10 Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature▼ 85/100 8840887 Grant: 2014-09-23 | Exp: 2034-09-18 Antibodies▼ 85/100 8778340 Grant: 2014-07-15 | Exp: 2034-07-10 Anti-angiogenesis therapy for the treatment of ovarian cancer▼ 82/100 8940302 Grant: 2015-01-27 | Exp: 2035-01-22 Predicting response to a HER inhibitor▼ 82/100 10975146 Grant: 2021-04-13 | Exp: 2041-04-08 Interleukin-1 inhibition for combination treatment of pancreatic cancer▼ 82/100 10758526 Grant: 2020-09-01 | Exp: 2040-08-27 Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways▼
Manufacturing (4) 92/100 9896478 Grant: 2018-02-20 | Exp: 2038-02-15 Antibody purification by cation exchange chromatography▼ 90/100 9441035 Grant: 2016-09-13 | Exp: 2036-09-08 Cell culture media and methods of antibody production▼ 85/100 10906986 Grant: 2021-02-02 | Exp: 2041-01-28 Prevention of disulfide bond reduction during recombinant production of polypeptides▼ 82/100 11680110 Grant: 2023-06-20 | Exp: 2043-06-15 Three-dimensional structure-based humanization method▼
Diagnostic (4) 92/100 12078638 Grant: 2024-09-03 | Exp: 2044-08-29 Diagnostic and therapeutic methods for cancer▼ 88/100 10031141 Grant: 2018-07-24 | Exp: 2038-07-19 VEGF polymorphisms and anti-angiogenesis therapy▼ 85/100 11402382 Grant: 2022-08-02 | Exp: 2042-07-28 Diagnostic and therapeutic methods for cancer▼ 82/100 10456470 Grant: 2019-10-29 | Exp: 2039-10-24 Diagnostic methods and compositions for treatment of glioblastoma▼